Biotron Limited (ASX:BIT) insider Robert Thomas purchased 1,000,000 shares of the business’s stock in a transaction on Friday, November 23rd. The shares were acquired at an average price of A$0.05 ($0.04) per share, for a total transaction of A$50,000.00 ($35,460.99).
Robert Thomas also recently made the following trade(s):
- On Friday, November 2nd, Robert Thomas purchased 1,004,793 shares of Biotron stock. The shares were acquired at an average price of A$0.06 ($0.04) per share, for a total transaction of A$60,287.58 ($42,757.15).
Biotron stock opened at A$0.16 ($0.11) on Friday.
Biotron Company Profile
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus.
Further Reading: What does earnings per share mean?
Receive News & Ratings for Biotron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotron and related companies with MarketBeat.com's FREE daily email newsletter.